FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder

FDA

8 October 2019 - The U.S. FDA today granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria.

The efficacy of Scenesse was established in two parallel group clinical trials with patients with erythropoietic protoporphyria who received Scenesse or placebo form of the implant subcutaneously every two months. The first clinical trial enrolled 93 subjects, of whom 48 received Scenesse, and were followed for 180 days.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US